Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya5900310.26442/00403660.2019.06.000281Research ArticleModern approaches to the detection of monoclonal gammopathy of undetermined significance (MGUS) in patients with kidney diseasesKozlovskaya(Lysenko)L. V-ChebotarevaN. Vnatasha_tcheb@mail.ruMrykhinN. N-RameevV. V-AndrosovaT. V-RoshchupkinaS. V-MaryinaS. A-KogarkoI. N-KogarkoB. S-Sechenov First Moscow State Medical University of the Ministry (Sechenov University)National Research Center for Hematology of the Ministry of Health of the Russian FederationSemenov Institute of Chemical Physics of the Russian Academy of Sciences15062019916677222012021Copyright © 2019, Consilium Medicum2019Monoclonal gammopathy (MG) is not only the state preceding of hematological neoplasms, but also associated with non - hematological diseases, in particular kidney damage. Aim. To assess the diagnostic value of “Freelite” methods in addition to electrophoresis (EF) and immunofixation (IF) of serum and urine proteins for detecting MG in patients with kidney diseases. Materials and methods. 87 patients with kidney damage, in which MG was established using the method of electrophoresis of serum proteins (EF), immunofixation (IF) and the method of free light chains determination - FLC “Freelite” were selected. The diagnostic value of three - component serum panel was compared with EF and IF. Results and discussion. AL-amyloidosis with kidney involvement was diagnosed in 41% patients, cryoglobulinemic glomerulonephritis (cryo GN) - in 18%, chronic glomerulonephritis (CGN) - in 35%, also there was small number of patients with light chain disease and cast - nephropathy. Determination of MG using EP was possible only in 38 (44%). Adding to the serum electrophoretic methods instead of the “Freelite” method, the urine EF and IF reduced the number of missed patients with monoclonal gammopathy from 24 (27%) to 11 (13%), including in the subgroup of patients with AL-amyloidosis but did not reach the sensitivity of the three - component serum screening panel. In 10 (11.5%) MG was represented only by intact mIg with one type of light chain, either κ or λ. Most often - in 25% of patients, intact monoclonal gammopathy was observed in HCV (+) cryo GN. A combination of intact mIgM, mIgG or mIgA with mFLC, was detected in 37 (42.5%). In almost half (46%) of the patients, only mFLC was detected - an abnormal κ/λ ratio. Conclusion: The serum screening panel EF + IF + “Freelite” spreads the low - grade monoclonal gammopathy recognition (MGUS) and should be included in the algorithm of examining patients with kidney disease.Freelitemonoclonal gammopathyimmunofixation of proteins“Freelite”amyloidosischronic glomerulonephritisмоноклональная гаммапатияметод иммунофиксацииамилоидозхронический гломерулонефрит[Leung N, Bridoux F, Hutchison C.A, Nasr S.H, Cockwell P, Fermand J.P, Dispenzieri A, Song K.W, Kyle R.A; International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-5. doi: 10.1182/ blood-2012-07-445304][Parry H, Pratt G, Hutchison C. Monoclonal gammopathy of undetermined significance: an update for nephrologists. Adv Chron Kidney Dis. 2012;19(5):291-6. doi: 10.1053/j.ackd.2012.07.006][Nasr S.H, Satoskar A, Markowitz G.S, Valeri A.M, Appel G.B, Stokes M.B, Nadasdy T, D'Agati V.D. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055-64. doi: 10.1681/ASN.2009010110][Bridoux F, Leung N, Hutchison C.A, Touchard G, Sethi S, Fermand J.P, Picken M.M, Herrera G.A, Kastritis E, Merlini G, Roussel M, Fervenza F.C, Dispenzieri A, Kyle R.A, Nasr S.H; International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698-711. doi: 10.1038/ki.2014.408][Hogan J.J, Weiss B.M. Bridging the divide: an onco - nephrologic approach to the monoclonal gammopathies of renal significance. Clin J Am Soc Nephrol. 2016;11(9):1681-91. doi: 10.2215/CJN.03160316][Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon J.M, Ronco P, Touchard G, Bridoux F. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy - associated C3 glomerulopathy. Blood. 2017;129(11):1437-47. doi: 10.1182/blood-2016-08-737163][Willrich M.A.V, Murray D.L, Kyle R.A. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin Biochem. 2018;51:38-47. doi: 10.1016/j.clinbiochem.2017.05.001][Katzmann J.A, Kyle R.A, Benson J, Larson D.R, Snyder M.R, Lust J.A, Rajkumar S.V, Dispenzieri A. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517-22. doi: 10.1373/clinchem.2009.126664][Dispenzieri A, Kyle R, Merlini G, Miguel J.S, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau J.L, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos M.V, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar S.V, Durie B.G; International Myeloma Working Group. International Myeloma Working Group guidelines for serum - free light chain analysis in multiple myeloma and related disorders. Leukemia. 209;23:215-24. doi: 10.1038/leu.2008.307][Dimopoulos M, Kyle R, Fermand J.P, Rajkumar S.V, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson K.C, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi N.C, Jagannath S; International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701-5. doi: 10.1182/blood-2010-10-299529][Hill P.G, Forsyth J.M, Rai B, Mayne S. Serum free light chains: an alternative test to urine Bence Jones proteins when screening for monoclonal gammopathies. Clin Chem. 2006;52:1743-8. doi: 10.1373/clinchem.2006.069104][Jenner E. Serum free light chains in clinical laboratory diagnostics. Clin Chim Acta. 2014;427:15-20. doi: 10.1016/j.cca.2013.08.018][Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani M.S, Melzi D'Eril G.V, Moratti R, Merlini G. Identification of amyloidogenic light chains requires the combination of serum - free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499-504. doi: 10.1373/clinchem.2008.117143][Katzmann J.A, Dispenzieri A, Kyle R.A, Snyder M.R, Plevak M.F, Larson D.R, Abraham R.S, Lust J.A, Melton L.J 3rd, Rajkumar S.V. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81(12):1575-8. doi: 10.4065/81.12.1575][Hutchison C, Basnayake K, Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol. 2009;5:621-7. doi: 10.1038/nrneph.2009.151][Katzmann J.A, Clark R.J, Abraham R.S, Bryant S, Lymp J.F, Bradwell A.R, Kyle R.A. Serum reference intervals and diagnostic ranges for free and free immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437-44. PMID: 12194920][Dispenzieri A, Katzmann J.A, Kyle R.A, Larson D.R, Melton L.J 3rd, Colby C.L, Therneau T.M, Clark R, Kumar S.K, Bradwell A, Fonseca R, Jelinek D.F, Rajkumar S.V. Prevalence and risk of progression of light - chain monoclonal gammopathy of undetermined significance: A retrospective population - based cohort study. Lancet. 2010;375:1721-8. doi: 10.1016/S0140-6736(10)60482-5][Keeling J, Herrera G.A. Matrix metalloproteinases and mesangial remodeling in light chain - related glomerular damage. Kidney Int. 2005;68(4):1590-603. doi: 10.1111/j.1523-1755.2005.00571.x][Basnayake K, Stringer S, Hutchison C, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79:1289-301. doi: 10.1038/ki.2011][Kapoulas S, Raptis V, Papaioannou M. New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. Nephrol Ther. 2015;11(3):135-43. doi: 10.1016/j.nephro.2014.12.005][Zhu L, Herrera G.A, Murphy-Ullrich J.E, Huang Z.Q, Sanders P.W. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor - beta. Am J Pathol. 1995;147(2):375-85.][Russell W.J, Cardelli J, Harris E, Baier R.J, Herrera G.A. Monoclonal light chain - mesangial cell interactions: early signaling events and subsequent pathologic effects. Lab Invest. 2001;81:689-703.][Teng J, Russell W.J, Gu X, Cardelli J, Jones M.L, Herrera G.A. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84(4):440-51. doi: 10.1038/labinvest.3700069][Keeling J, Teng J, Herrera G.A. AL-amyloidosis and light - chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest. 2004;84(10):1322-38.][Meri S, Koistinen V, Miettinen A, Tornroth T.G, Seppala I.J.T. Activation of the alternative pathaway of complement by monoclonal lambda L chains in membranoproliferative glomerulonephritis. J Exp Med. 1992;175:939-50.][Jokiranta T.S, Solomon A, Pangburn M.K, Zipfel P.F, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against factor H. J Immunol. 1999;163:4590-6.][Knight G.B, Gao L, Gragnani L, Elfahal M.M, De Rosa F.G, Gordon F.D, Agnello V. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryo - globulinemic vasculitis and B cell malignancies. Arthritis Rheum. 2010;62:2152-9. doi: 10.1002/art.27490][Wang P.X, Sanders P.W. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol. 2007;18(4):1239-45. doi: 10.1681/ASN.2006111299][Sethi S, Fervenza F.C, Rajkumar S.V. Spectrum of manifestations of monoclonal gammopathy - associated renal lesions. Curr Opin Nephrol Hypertens. 2016;25:127-37. doi: 10.1097/MNH.0000000000000201][Zakharova E.V, Stolyarevich E.S, Vorobyeva O.A, Nikitin E.A Combined immunoglobulin G kappa nephropathy: Monoclonal immunoglobulin deposition disease and proximal tubulopathy: monoclonal gammopathy of renal significance or smoldering multiple myeloma? Case report and review of literature. Integr Cancer Sci Therap. 2017;4(1):1-9. doi: 10.15761/ICST.1000225]